CRA leverages its deep industry knowledge and familiarity with healthcare data analytics to help our clients navigate government investigations involving civil, criminal, and regulatory enforcement issues. We have expertise in pharmaceutical pricing and reimbursement and the intersection of these areas with government regulations. Our team has experience working with complex data, including Medicare, Medicaid, and private insurance claims data, pharmaceutical sales data, and market research to investigate questions of wrongful conduct, causation and damages.
- 01CRA addresses U.S. government healthcare programs and pharmaceutical pricing in False Claims Act suitIn this whistleblower suit, a relator alleged Bristol-Myers Squibb Co. (“BMS”) violated the False Claims Act and various state claims. The suit alleged that...View engagement
- 02CRA assesses distributor practices for controlled substancesCRA was retained by distributors of pharmaceutical products in national litigation relating to opioid products. CRA addressed claims by state and local...View engagement
- 03CRA evaluates Canadian pharmaceutical pricingCRA provided expert testimony in multiple proceedings before the Patented Medicine Prices Review Board (PMPRB) in relation to alleged excessive pricing by...View engagement